AC
ACXP icon

Armistice Capital’s Acurx Pharmaceuticals ACXP Stock Holding History

Armistice Capital’s Portfolio ACXP Stock Details ACXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-53,927
Closed -$551K – 329
2025
Q2 		$551K Buy
+53,927
New +$434K 0.01% 157
2023
Q4 		– Sell
-25,000
Closed -$750K – 297
2023
Q3 		$750K Sell
25,000
-34,100
-58% -$1.3M 0.01% 153
2023
Q2 		$3.13M Buy
59,100
+45,100
+322% +$2.69M 0.05% 130
2023
Q1 		$969K Sell
14,000
-30,000
-68% -$2.19M 0.01% 140
2022
Q4 		$3.5M Sell
44,000
-9,300
-17% -$612K 0.06% 109
2022
Q3 		$3.2M Buy
+53,300
New +$3.99M 0.06% 113

Other funds holding ACXP

PFS
Prospect Financial Services Melville, New York $164M AUM 19.24% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.33B AUM 24% 1-Year Est. Return
CPG
Cornerstone Planning Group Fairfield, New Jersey $749M AUM 17.97% 1-Year Est. Return
GWSG
GPS Wealth Strategies Group Centennial, Colorado $117M AUM 24.22% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Armistice Capital's ACXP Position: Q3 2025 in Review

Armistice Capital sold out of Acurx Pharmaceuticals (ACXP) in Q3 2025, closing a stake of 53,927 shares — an estimated $551K sold.

Armistice Capital first reported a position in ACXP in Q3 2022 and held it in 6 quarters. The position peaked at $3.5M in Q4 2022. 16 funds tracked by Wall St. Rank hold ACXP as of Q3 2025.

  • Armistice Capital reported no remaining Acurx Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Armistice Capital sold 53,927 Acurx Pharmaceuticals shares in Q3 2025, an estimated $551K.
  • Armistice Capital first reported a position in Acurx Pharmaceuticals in Q3 2022 and held it in 6 quarters.
  • Armistice Capital's Acurx Pharmaceuticals position peaked at $3.5M in Q4 2022.
  • 16 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q3 2025.

Based on Armistice Capital's 13F filing for Q3 2025, filed 17 Nov 2025.